以血管活性肠肽瘤为首发表现的1型多发性内分泌腺瘤病一例报道  

VIPoma acts as the primary manifestation of MEN1: one case report

作　　者：郭小青 高月 薛建锋[2] 王晓娟[3] 任高飞[1] 刘艳霞[1] 邢晶晶[1] 栗夏莲[1] Guo Xiaoqing;Gao Yue;Xue Jianfeng;Wang Xiaojuan;Ren Gaofei;Liu Yanxia;Xing Jingjing;Li Xialian(Department of Endocrinology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,China;Department of Hepatobiliary Pancreas,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,China;Department of Pathology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450000,China)

机构地区：[1]郑州大学第一附属医院内分泌科,450000 [2]郑州大学第一附属医院肝胆胰科,450000 [3]郑州大学第一附属医院病理科,450000

出　　处：《中华内分泌代谢杂志》2019年第4期337-340,共4页Chinese Journal of Endocrinology and Metabolism

摘　　要：多发性内分泌腺瘤病1型(multiple endocrine neoplasia type1, MEN1)是一种累及2个及以上内分泌腺体的肿瘤综合征,甲状旁腺、胰腺及垂体为最常累及的腺体,其中胰血管活性肠肽瘤(vasoactive intestinal peptide tumor, VIPoma )极其罕见,VIPoma最早于1958年由Verner和Morrison报道[1],发病率约为1/1000万[2],约占MEN1的5%[3],以顽固性水样腹泻、低钾血症、无胃酸或低胃酸分泌的综合征(WDHA综合征)为特点。

关 键 词：多发性内分泌腺瘤病 胰血管活性肠肽瘤 首发表现 VIPOMA peptide WDHA综合征 肿瘤综合征 内分泌腺体 

分 类 号：R736[医药卫生—肿瘤]